Introduction
============

Liver failure resulting from hepatitis B (HBV) represents difficult-to-treat conditions. Molecular Adsorbents Recirculating System (MARS) liver support is a novel therapy, but few data on patients of HBV are available.

Methods
=======

This report is a review of MARS on patients with liver failure suffered from HBV. Data were extracted from official journals until September 2003; 149 patients with 347 treatments in China were eligible with available detailed data (mean age was 44.3 ± 13.2 \[15--80\] years, 102 males, average treatments 2.33 per patient).

Results
=======

MARS treatments were associated with a significant reduction of albumin-bound toxins and various cytokines, as well as the water-soluble toxins. Most patients showed a positive response to the therapy, proven by an increase in prothrombin time activity and mean arterial pressure, and a decrease in hepatoencephalo-pathy grade and Child--Turcotte--Pugh index significantly.

Eighty-four patients survived in hospital including those alive from the liver transplantation (56.4%). Survival of the acute liver failure, subacute liver failure and acute on chronic liver failure patients were 62.5%, 66.7% and 54.5%, and acute on chronic liver failure patients formed the majority (121/149--81.2%). Patients in end stage presented the largest among the subgroups of acute on chronic liver failure (65/121, 53.7%), and patients in the early and middle stages gained more favorable outcomes than those in C grade (91.7% and 75% vs 30.8%) (Table [1](#T1){ref-type="table"}).

  Type            Total *n*   Survival *n*(Re + OLT)   Death *n*(%)
  --------------- ----------- ------------------------ --------------
  ALF             16          10 (8 + 2) (62.5%)       6 (37.5%)
  SALF            12          8 (8 + 0) (66.7%)        4 (33.3%)
  AoCLF                                                
   Early stage    24          22 (20 + 2) (91.7%)      2 (8.3%)
   Middle stage   32          24 (21 + 3) (75%)        8 (25%)
   End stage      65          20 (18 + 2) (30.8%)      45 (69.2%)
  Total           149         84 (75 + 9) (56.4%)      65 (43.6%)

ALF, acute liver failure; AoCLF, acute on chronic liver failure; OLT, orthotopic liver transplantation; SALF, subacute liver failure.

Randomized controlled studies in China are ongoing to verify the optimal therapeutic results of MARS.
